Abstract
Introduction
This analysis examines the historical and forecast performance for Amgen in
the prescription pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Key reasons to purchase this research
- Benchmark Amgen' s performance against key rivals in the prescription
pharmaceutical sector
- Assess how Amgen' s commercial performance out to 2014 will be impacted by
the safety concerns relating to the ESA product class
- Analyze Amgen' s diversification strategy which will be heavily reliant on
the launch of the cross-therapy area monoclonal antibody Prolia
| 
View Cart
